What Paradigm Biocapital Advisors LP reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1855655 · Filed Nov 16, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 14.1M |
| +7.6% |
| $504.3M |
| 10% |
EWTXEdgewise Therapeutics, Inc. | 10.8M | +5.5% | $437.6M | 8.7% |
SYRESpyre Therapeutics, Inc. | 4.5M | +16.1% | $396.8M | 7.9% |
INSMInsmed Inc | 2.7M | +103.3% | $307.7M | 6.1% |
MBXMBX Biosciences, Inc. | 3.8M | +50.4% | $221.2M | 4.4% |
ORKAOruka Therapeutics, Inc. | 2.5M | +16.3% | $207.7M | 4.1% |
BLTEBelite Bio, Inc | 1.1M | −7.4% | $194M | 3.9% |
TARSTarsus Pharmaceuticals, Inc. | 2.3M | −17.1% | $180.9M | 3.6% |
TNGXTango Therapeutics, Inc. | 7M | +9.5% | $173.7M | 3.5% |
VRDNViridian Therapeutics, Inc.DE | 8.3M | +22.8% | $170M | 3.4% |
BBIOBridgeBio Pharma, Inc. | 2.3M | New | $154.5M | 3.1% |
PCVXVaxcyte, Inc. | 2.1M | +0.7% | $121.9M | 2.4% |
ERASErasca, Inc. | 8M | −16.2% | $117.3M | 2.3% |
JBIOJade Biosciences, Inc. | 6.1M | +111.8% | $85M | 1.7% |
TYRATyra Biosciences, Inc. | 3.5M | +92.0% | $76.8M | 1.5% |
OLMAOlema Oncology, Inc. | 8.7M | +0.6% | $75.3M | 1.5% |
OBXObsidian Therapeutics, Inc. | 4.2M | New | $57.1M | 1.1% |
GPCRStructure Therapeutics Inc. | 1.3M | New | $40.6M | 0.8% |
ACHVAchieve Life Sciences, Inc. | 5M | ±0% | $40.1M | 0.8% |
MANEVeradermics, Inc | 310.1K | New | $37.6M | 0.7% |
ASMBAssembly Biosciences, Inc. | 1.6M | ±0% | $36.5M | 0.7% |
ORICOric Pharmaceuticals, Inc. | 1.5M | New | $20.3M | 0.4% |
KRSAKorsana Biosciences, Inc. | 613.9K | New | $19.6M | 0.4% |
EDITEditas Medicine, Inc. | 7.6M | +35.6% | $19.5M | 0.4% |
COAGHemab Therapeutics Holdings, Inc. | 629.3K | New | $19.4M | 0.4% |
VORVor Biopharma Inc. | 889.6K | −49.2% | $17M | 0.3% |
KARDKardigan, Inc. | 900K | ±0% | $13.3M | 0.3% |
TCGXTCGX Acquisition Corp. | 300K | New | $3.8M | 0.1% |
IVAInventiva S.A. | 808.2K | −79.8% | $3M | 0.1% |